PBYI

Puma Biotechnology Inc

PBYI, USA

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

https://www.pumabiotechnology.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PBYI
stock
PBYI

Aug Rallies: vuot qua song gio cuoc doi - Quarterly Profit Report & Daily Technical Forecast Reports moha.gov.vn

Read more →
PBYI
stock
PBYI

With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case Sahm

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$3.5

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

6.58

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

High

2.58

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

7.67 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.36 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

17.74 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.76

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 59.63% of the total shares of Puma Biotechnology Inc

1.

BlackRock Inc

(7.615%)

since

2025/06/30

2.

Vanguard Group Inc

(7.3583%)

since

2025/06/30

3.

Renaissance Technologies Corp

(3.7218%)

since

2025/06/30

4.

American Century Companies Inc

(2.6648%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(2.5539%)

since

2025/07/31

6.

Avantis US Small Cap Value ETF

(2.4218%)

since

2025/08/30

7.

Dimensional Fund Advisors, Inc.

(2.2832%)

since

2025/06/30

8.

iShares Russell 2000 ETF

(2.0979%)

since

2025/08/31

9.

Kennedy Capital Management Inc

(1.9595%)

since

2025/06/30

10.

Geode Capital Management, LLC

(1.929%)

since

2025/06/30

11.

Connor Clark & Lunn Inv Mgmt Ltd

(1.7873%)

since

2025/06/30

12.

Vanguard Explorer Inv

(1.5433%)

since

2025/06/30

13.

HHG PLC

(1.4801%)

since

2025/06/30

14.

State Street Corp

(1.4584%)

since

2025/06/30

15.

Kennedy Micro Cap

(1.2907%)

since

2025/06/30

16.

D. E. Shaw & Co LP

(1.2721%)

since

2025/06/30

17.

Vanguard Strategic Equity Inv

(1.0729%)

since

2025/06/30

18.

LSV Asset Management

(1.0636%)

since

2025/06/30

19.

Citadel Advisors Llc

(1.0082%)

since

2025/06/30

20.

GlobeFlex Capital, L.P.

(0.8985%)

since

2025/06/30

21.

Arrowstreet Capital Limited Partnership

(0.8966%)

since

2025/06/30

22.

Los Angeles Capital Management LLC

(0.8844%)

since

2025/06/30

23.

O'Shaughnessy Asset Management LLC

(0.8689%)

since

2025/06/30

24.

Fidelity Small Cap Index

(0.8482%)

since

2025/06/30

25.

Vanguard Institutional Extnd Mkt Idx Tr

(0.799%)

since

2025/07/31

26.

iShares Russell 2000 Value ETF

(0.7305%)

since

2025/08/31

27.

SEI Investments Co

(0.6894%)

since

2025/06/30

28.

Bank of New York Mellon Corp

(0.6831%)

since

2025/06/30

29.

Kennedy Micro Cap Opportunities

(0.6688%)

since

2025/06/30

30.

Millennium Management LLC

(0.6643%)

since

2025/06/30

31.

Acadian Global Small-Cap Equity CIT Cl A

(0.6292%)

since

2025/03/04

32.

PGIM Quant US Small Cap value Equity

(0.541%)

since

2025/06/30

33.

PGIM Quant Solutions Small-Cap Val Z

(0.5263%)

since

2025/07/31

34.

BlackRock Advantage Small Cap Core Instl

(0.4417%)

since

2025/07/31

35.

Vanguard Russell 2000 ETF

(0.403%)

since

2025/07/31

36.

Fidelity Extended Market Index

(0.3882%)

since

2025/07/31

37.

Federated Hermes MDT Small Cap Growth IS

(0.3847%)

since

2025/06/30

38.

Federated Hermes MDT SCG Institutional

(0.3847%)

since

2025/06/30

39.

DFA US Small Cap I

(0.382%)

since

2025/07/31

40.

DFA US Targeted Value I

(0.3405%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.21

EPS Estimate

0.155

EPS Difference

0.055

Surprise Percent

35.4839%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.5)
GARP
Fair GARP(6)
Growth
Moderate Growth(5)
Momentum
Strong Momentum(7)
Net Net
Possible Net-Net(3.5)
Quality
High Quality(7.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.